The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Getting stronger
Did people actually get stronger, or just bigger?
Measured strength, not measured size. A compound can add lean mass on a scan and move nothing a person can feel.
2,413 people · 30 human studies · 25 compounds
- 603 people1 study
CREATE: 603 people with estimated GFR 15 to 35 randomised to a normal (13.0 to 15.0 g/dL) or subnormal (10.5 to 11.5 g/dL) haemoglobin target using epoetin beta, 3 years. First cardiovascular events 58 versus 47, hazard ratio 0.78, 95 percent confidence interval 0.53 to 1.14, p = 0.20. More people in the normalisation...
New England Journal of Medicine, 2006 · 603 people
- 538 people1 study
Whole purified venom, not melittin. 538 patients with knee osteoarthritis randomised 1:2 to histamine control or 100 mcg venom in 15 dermal injections at acupuncture points weekly for 12 weeks. WOMAC pain improved 1.1 points more than control (95% CI 0.3 to 2.0, p = 0.001) and physical function 3.1 points (p =...
Journal of Alternative and Complementary Medicine, 2019 · 538 people
- 299 people1 study1 found nothing
found nothing299 participants randomised to placebo or 2 g a day of carnosine, with hand grip strength, bilateral calf raise, two-minute step test and gait speed measured at baseline and at roughly 6 and 12 weeks. Results were subgroup-only: a significant increase in calf raises at visit 3 in participants under 40 (P equal to...
Journal of the International Society of Sports Nutrition, 2026 · 299 people
- 233 people2 studies1 found nothing
found nothingThe pharmaceutical-grade version of this molecule in 233 older adults with sarcopenia. The primary endpoint, gait speed on a 400-metre walk, improved 0.07 m/s against placebo in the full analysis set and was not significant, and improved 0.09 m/s in the per-protocol population at p = 0.008. Detail on the BIO101 page.
Journal of Cachexia, Sarcopenia and Muscle, 2025 · 233 people
A controlled clinical trial in humans. Significantly higher increases in muscle mass in participants dosed with ecdysterone, and significantly more pronounced increases in one-repetition bench press performance. The same hypertrophic effect appeared in C2C12 myotubes in vitro. No increase in liver or kidney toxicity...
Archives of Toxicology, 2019 · no headcount in the line
- 201 people1 study1 found nothing
found nothing201 older adults randomised, 99 to placebo and 102 to the antibody, from 365 screened. At 24 weeks appendicular lean body mass changed by minus 0.123 kg on placebo and plus 0.303 kg on drug, a difference of 0.43 kg (95% CI 0.192 to 0.660, p < 0.0001). On function: twelve-step stair climb minus 1.28 s (p = 0.011),...
Lancet Diabetes and Endocrinology, 2015 · 201 people
- 123 people1 study
123 elderly hip-fracture patients: gait speed improved and IGF-1 rose, but most functional measures did not, and the trial was terminated early over a congestive heart failure safety signal.
Archives of Gerontology and Geriatrics, 2011 · 123 people
- 116 people1 study
116 adults with Becker, facioscapulohumeral or limb-girdle muscular dystrophy, randomised, double-blind, placebo-controlled, across four dose cohorts from 1 to 30 mg/kg. Safety and tolerability were good apart from cutaneous hypersensitivity at 10 and 30 mg/kg. Verbatim: there were no improvements noted in exploratory...
Annals of Neurology, 2008 · 116 people
- 90 people1 study
90 patients: 6 months of NR improved 6-minute walk distance by 17.6 m versus placebo, a first functional outcome.
Nature Communications, 2024 · 90 people
- 80 people1 study1 found nothing
found nothing60-day RCT in 80 adults: 300 to 900 mg/day raised blood NAD and modestly improved six-minute walk distance; well tolerated; HOMA-IR unchanged.
GeroScience, 2023 · 80 people
- 50 people1 study1 found nothing
found nothingSARA-INT. 233 randomised, mean age 75.5, 54.3% female, three arms at 175 mg twice daily, 350 mg twice daily or placebo, planned six months and up to nine in 50 subjects. Eligibility required meeting FNIH sarcopenia criteria and a Short Physical Performance Battery score of 8 or less out of 12. Primary endpoint was...
Journal of Cachexia, Sarcopenia and Muscle, 2025 · 50 people
- 30 people1 study1 found nothing
found nothing30 healthy men, mean age 71, randomised to 2.5 g leucine or placebo with each main meal, 7.5 g daily for three months. No change in skeletal muscle mass measured by computed tomography and DXA, and no change in one-repetition-maximum strength, in either group. No improvement in whole-body insulin sensitivity, HbA1c or...
American Journal of Clinical Nutrition, 2009 · 30 people
- 14 people2 studies
14 patients: D+Q was feasible and improved 6-minute walk, gait speed and chair-stand time; no control group.
EBioMedicine, 2019 · 14 people
The same team's open-label pilot repeated with a placebo arm, n=12: frailty, pulmonary and physical function did not appear to differ meaningfully between groups, and the drug arm reported 65 non-serious adverse events against 22 on placebo.
EBioMedicine, 2023 · no headcount in the line
- 14 people2 studies
Open-label pilot in 14 IPF patients: improved physical function measures; adverse events mostly mild to moderate.
EBioMedicine, 2019 · 14 people
The same team's open-label pilot repeated with a placebo arm, n=12: frailty, pulmonary and physical function did not appear to differ meaningfully between groups, and the drug arm reported 65 non-serious adverse events against 22 on placebo.
EBioMedicine, 2023 · no headcount in the line
- 12 people2 studies
AAV1-delivered FS344 injected into the quadriceps of six patients: four improved six-minute walk distance (29 to 125 m), no adverse effects, reduced fibrosis on biopsy.
Molecular Therapy, 2015 · 6 people
Six treated patients gained a median 56 m/year on six-minute walk versus a 26 m/year decline in matched untreated controls; small, non-randomized.
Molecular Therapy, 2017 · 6 people
- 10 people1 study
Ten Barth syndrome patients in the open-label extension: 6-minute walk distance improved cumulatively by 96.1 m at week 168 with injection-site reactions the most common adverse event.
Genetics in Medicine, 2024 · 10 people
- no headcount stated2 studies1 found nothing
found nothing4 months of urolithin A improved muscle endurance and plasma biomarkers, though 6-minute walk and peak ATP did not differ from placebo.
JAMA Network Open, 2022 · no headcount in the line
About 12% gain in muscle strength and improved VO2 peak and 6-minute walk, though the primary peak-power endpoint was not met.
Cell Reports Medicine, 2022 · no headcount in the line
- no headcount stated1 study
The trial was stopped after the second dose level because of epistaxis and telangiectasias; only non-significant trends toward preserved six-minute walk and higher lean mass were seen.
Muscle and Nerve, 2017 · no headcount in the line
- no headcount stated1 study
24 weeks of GlyNAC in older adults corrected glutathione deficiency and improved strength, gait speed and cognition; benefits faded after stopping.
Clinical and Translational Medicine, 2021 · no headcount in the line
- no headcount stated1 study
Mouse data plus an initial proof-of-concept in humans: 7 days of (-)-epicatechin increased hand grip strength and the plasma follistatin to myostatin ratio. Small, uncontrolled and short; this is the study most supplement marketing traces back to.
Journal of Nutritional Biochemistry, 2014 · no headcount in the line
- no headcount stated1 study
The human trial turkesterone's reputation is borrowed from, and it tested a different molecule. Ecdysterone increased muscle mass and one-repetition bench press performance in a controlled human trial. Nothing in it concerns turkesterone.
Archives of Toxicology, 2019 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingThe T-Trials. Treatment raised testosterone into the mid-normal range for men aged 19 to 40. Sexual activity, sexual desire and erectile function all improved significantly. Vitality did not improve on the fatigue scale. The proportion improving 6-minute walking distance by at least 50 m did not differ in the Physical...
New England Journal of Medicine, 2016 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingIncluded as the contrast, and it is not urolithin B. This is a randomised trial of urolithin A in older adults, in which muscle endurance and plasma biomarkers improved while the six-minute walk and peak ATP did not differ from placebo. Urolithin B has no trial of this kind, or of any kind.
JAMA Network Open, 2022 · no headcount in the line
- no headcount stated1 study
As previously published, MMPOWER-3 did not demonstrate a significant benefit of elamipretide in a genotypically diverse adult population with primary mitochondrial myopathy. In post hoc analysis the mitochondrial DNA replisome cohort improved 25.2 plus or minus 8.7 metres on the six-minute walk test against 2.0 plus...
Orphanet Journal of Rare Diseases, 2024 · no headcount in the line
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.